Concepedia

Author

Sandra Tomek

Vienna General Hospital

Also Known As

SANDRA TOMEK, Sandra Tomek

20

Publications

726

Citations

12

H-Index

31

Concepts

All Affiliations

Vienna General HospitalLudwig Boltzmann Institute for Traumatology, The Research Center in Cooperation with AUVALudwig Boltzmann Institute for Digital Health and PreventionMedical University of Vienna
ST

About

Sandra Tomek is an author at Vienna General Hospital specializing in medicine, oncology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

131

2

Public Health

1

1

11

3

Biochemistry

1

1

11

4

Biomedical Engineering

1

1

11

5

Cell Biology

1

1

11

Sandra Tomek

×

12

Publications

627

Citations

11

H-Index

YearCitations

Contribution of Epigenetic Silencing of Tumor Necrosis Factor–Related Apoptosis Inducing Ligand Receptor 1 (DR4) to TRAIL Resistance and Ovarian Cancer

Peter Horak, Dietmar Pils, Griet Haller,

Molecular Cancer Research

2005

148

Monitoring of Serum Her-2/<b> <i>neu</i> </b> Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer

Wolfgang J. Köstler, Barbara Schwab, Christian F. Singer,

Clinical Cancer Research

2004

144

<sup>11</sup>C-Acetate Positron Emission Tomography Imaging and Image Fusion With Computed Tomography and Magnetic Resonance Imaging in Patients With Recurrent Prostate Cancer

Stefan De Wachter, Sandra Tomek, Amir Kurtaran,

Journal of Clinical Oncology

2006

109

Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs

Sandra Tomek, Peter Horak, Ingrid Pribill,

Gynecologic Oncology

2004

54

Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer

Thomas Brodowicz, Roswitha Wolfram, Wolfgang J. Köstler,

Anti-Cancer Drugs

2000

37

Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer.

Wolfgang J. Köstler, Günther Steger, Afschin Soleiman,

PubMed

2004

34

Soluble ICAM-1 in breast cancer: clinical significance and biological implications

Wolfgang J. Köstler, Sandra Tomek, Thomas Brodowicz,

Cancer Immunology Immunotherapy

2001

25

Recurrent malignant Triton tumour: first report on a long time survivor.

Wolfgang J. Köstler, Gabriele Amann, Thomas W. Grunt,

PubMed

2003

21

Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer

Peter Horak, Dietmar Pils, Max Roessler,

Gynecologic Oncology

2005

20

Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer

Thomas Brodowicz, W. Koestler, Sandra Tomek,

Anti-Cancer Drugs

2000

13

Page 1